source
- Commenters urge FDA to allow flexible trial designs for rare diseases, questioning RCT emphasisStakeholders who submitted comments to the FDA’s public docket on statistical methods for rare disease studies emphasized the need for greater flexibility in how trials are designed and what types…
- FDA faces push for flexible rare-disease trial designs as commissioner's nomination withdrawnThe FDA’s weekly briefing highlighted several notable developments, including the sudden withdrawal of the Trump administration’s nominee for FDA commissioner at the last minute. The agency also a…